

Corporate Presentation



Hanmi Pharmaceutical Co., Ltd.

Forward-Looking Statements

This presentation contains forward-looking statements with respect to future financial condition, results of operations and businesses of Hanmi Pharmaceutical Company. By their nature, forward-looking statements and forecasts involve risk and uncertainties because they relate to events and circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed in or implied by the forward-looking information and statements. These risks and uncertainties include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities. Hanmi does not undertake any obligation to update or revise any forward-looking information or statements.

Our Businesses

Strong Strategic Alliances around the Globe

“We value our partners and our innovation”

Hanmi

Beijing Hanmi

- Sales and Marketing
- Manufacturing
- PENTAMBODY Platform (BsAb)

- 6 R&D Centers
- 3 Manufacturing sites
- LAPSCOVERY Platform (Biologics)
- NCE Discovery (Small molecule)

SANOFI

Genentech
A Member of the Roche Group

MSD

SPECTRUM
PHARMACEUTICALS

Athenex

RAPT
THERAPEUTICS

SANDOZ

teva

Allegro
OPHTHALMICS, LLC

Innovent
信达生物制药

Phanes
Therapeutics

Major R&D Achievements

History of Global Collaborations with partners

“The Way to Sustain Innovation and Growth”

 MSD Amosartan <i>Amlodipine+Losartan</i>	 SPECTRUM Eflapegrastim <i>Long acting GCSF analog</i>	 teva Hyalrheuma <i>Hyaluronate</i>	 SANOFI Efpeglenatide <i>Weekly GLP-1</i>	 Genentech <i>A Member of the Roche Group</i> Belvarafenib <i>RAF inhibitor</i>	 MSD Rosuzet <i>Rosuvastatin +Ezetimibe</i>	 RAPT FLX475 <i>CCR4 inhibitor, Immuno-Oncology</i>
2009	2012	2014	2016	2018		
	2011  Athenex Orascovery Platform Tech <i>Oral Paclitaxel / Irinotecan</i>	2013  SANOFI Rovelito <i>Irbesartan+Atorvastatin</i>	2015  SPECTRUM Poziotinib <i>Pan-HER inhibitor</i>	2017  Innovent <i>信达生物制药</i> Anti-PD-1/HER2 Bi-specific antibody <i>Targeted Immuno-Oncology</i>	2019  Phanes Therapeutics New Antibody Sequence <i>Immuno-Oncology</i>	

The True Innovation should

Embrace patients with rare disease

Rare Disease Programs in Clinical Stage

Congenital Hyper-insulinism (CHI)	Short Bowel Syndrome (SBS)	Acute Myeloid Leukemia (AML)	Fabry & Maroteaux-Lamy syndrome
Weekly Glucagon Orphan Drug Designation in US & EU	Monthly GLP-2 Orphan Drug Designation in US & EU	FLT3 inhibitor Orphan Drug Designation in US	Monthly enzyme Replacement Therapy

Innovative R&D Pipeline (Jan 2020)

8 Obesity/NASH Diabetes

13 Oncology

4 Rare Diseases 3 Others

Pre-Clinical	Phase 1	Phase 2	Phase 3	Registration
HM14320 (^{1st} LAPS Glucagon Combo) Obesity/NASH/Diabetes	HM15211 (^{1st} LAPS Triple Agonist) NASH	HM12525A (^{1st} LAPS GLP/GCG) Obesity	Efpeglenatide (^{1st} LAPS Exd4 Analog) Diabetes SANOFI	
HM14220 (^{1st} LAPS Insulin Combo) Diabetes SANOFI	HM15136 (^{1st} LAPS Glucagon Analog) Obesity			
HM12480 (^{1st} LAPS Insulin148) Diabetes	HM12460A, HM12470 (^{1st} LAPS Insulin) - Diabetes			
Undisclosed BsAb Sequence Targeted immuno-oncology Pharmers	Belvarafenib (Pan-RAF Inhibitor) Solid tumor Genentech	Pozitotinib (Pan-HER Inhibitor) NSCLC & Breast cancer SPECTRUM	Oraxol (Oral Paclitaxel + Encequidar) Metastatic Breast cancer Athenex	Rolontis® (Eflapegrastim) Neutropenia SPECTRUM
HM97594 (EZH1/2 Dual Inhibitor) Hematol. malignancies	HM43239 (FLT3 Inhibitor) AML	Oratecan (Oral Irinotecan + Encequidar) Solid tumor Athenex		
HM87171 (ADOR Antagonist) Cancer Immunotherapy	IBI315/BH2950 (PD-1/HER2 BsAb) Targeted immuno-oncology Innovent	Oradoxel (Oral Docetaxel + Encequidar) Solid tumor Athenex		
HM97346 (LSD1 Inhibitor) Solid tumors/Hematol. malignancies	FLX475 (CCR4 inhibitor) Solid tumor RAPT			
HM15450 (^{1st} LAPS ASB) Mucopolysaccharidosis	HM15136 (^{1st} LAPS Glucagon Analog) Congenital hyperinsulinism	Efpegsomatropin (^{1st} LAPS hGH) GH deficiency		
	HM15912 (^{1st} LAPS GLP-2 Analog) Short bowel syndrome	Luminate® (Integrin inhibitor) Diabetic Macular Edema Allegro		
	Luminate® (Integrin inhibitor) Retinitis Pigmentosa Allegro	HM71224 (BTK Inhibitor) Autoimmune/Allergic diseases		

Thank you

 **Hanmi Pharmaceutical Co., Ltd.**